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pluripotency. Whether this reflects the
developmental status of the ICM at the
time of ESC derivation or differential
signaling requirements for the mainte-
nance of pluripotency (Roode et al.,
2011) should be further explored. In the
meantime, extrapolation from mouse
pluripotent stem cell data to inform
primate stem cell biology is likely to be
inadequate. For this reason, it is important
to encourage human stem cell biologists
to avoid false expectations from other
species such as the mouse. However,
if primate pluripotent stem cells can be
returned to the naive state of pluripo-
tency, their unequivocal value may befurther enhanced, and mouse models
may become more informative for human
medicine.
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Although metastasis is a major cause of morbidity and mortality in patients with pancreatic cancer,
the requisite events are currently unknown. In this issue ofCell, Haeno et al. and Rhim et al. propose
that metastasis occurs much earlier than previously anticipated, with clear implications for
improving patient care.Pancreatic cancer is the most lethal
common malignancy, despite standardi-
zation of surgical techniques and ad-
vances in systemic treatments. Most
pancreatic cancer patients present with
inoperable disease and rapidly succumb
from a devastating illness characterized
by tumor spread and vital organ dysfunc-
tion, intractable pain, galloping cachexia,
and coagulopathy. Surgical resection
offers the only hope for cure in the 20%
of patients who qualify, yet few survive
longer than 5 or 10 years, and the distin-
guishing features of this subgroup of
patients are unknown. Systemic chemo-
therapy provides temporary benefits inadvanced disease, whereas it prolongs
survivalmeasurably in the adjuvant setting
presumably by targeting microscopic
foci of local and distant disease. Recent
intriguing genomic analyses of pancreatic
tumors proposed that the initial primary
tumor proliferates for several years before
producing metastatic clones (Yachida
et al., 2010); however, patients with very
small or clinically undetectable primary
tumors still have a high risk of developing
metastases. Therefore, understanding
the mechanistic details and temporal
pattern of pancreatic cancer metastasis
is critical for designing effective interven-
tions, as explored in this issue of Cell intwo articles by Rhim et al. (2012) and
Haeno et al. (2012).
A traditional view of cancer metastasis
seeks to identify the ‘‘seed and soil’’
factors that may promote this process.
Along these lines, it is pertinent to
consider the genetic rap sheet of the
most common form of pancreatic cancer
(pancreatic ductal adenocarcinoma or
PDAC), as the four hallmark mutations of
PDAC (KRAS [>90%], p16INK4A [>90%],
TP53 [70%], and SMAD4 [55%]) have
all previously been implicated in themeta-
static process in human samples and
genetically engineered mouse models.
Indeed, oncogenic KRAS is known to8, January 20, 2012 ª2012 Elsevier Inc. 21
Figure 1. Metastasis in Pancreatic Cancer
Normal pancreatic ductal cells do not show invasion into stroma or extravasation, whereas PanIN cells
and PDAC cells are capable of this behavior. The capacity to colonize effectively is restricted to trans-
formed cells (PDAC).stimulate cellular migration and permit
survival in limiting nutrients, effects that
may be accentuated when the wild-type
KRAS allele is lost as observed in metas-
tases (Qiu et al., 2011). Deletion of the
Ink4a/ARF locus in Kras mutant pancre-
atic cells promotes Notch and NF-kB
signaling and metastasis in mouse
models (reviewed in Mazur and Siveke,
2011); likewise, point mutant TrP53 alleles
possess neomorphic properties that
promote tissue invasion and metastasis
by stimulating integrin/EGFR signaling
(Muller et al., 2009). Finally, Smad4 loss
promotes PDAC metastasis in mice (re-
viewed in Mazur and Siveke, 2011), and
SMAD4 loss correlates with high meta-
static burden clinically (Iacobuzio-Dona-
hue et al., 2009). The ‘‘soil’’ counterpart
of pancreatic cancer has also been impli-
cated whereby the tumor fibroblasts/
activated pancreatic stellate cells comi-
grate with PDAC cells to promote metas-
tasis in a transplantation model system
(Xu et al., 2010). Also, the uniquely hypo-
vascular nature of PDAC (reviewed in
Mazur and Siveke, 2011) could conceiv-
ably promote hypoxia and hence meta-
static behavior. Therefore, and without
precluding the possibility of additional
cooperating events (both genetic and
non-), all PDAC cells are in principal
destined to metastasize.
Metastasis describes a continuum
beginning with the invasion by carcinoma22 Cell 148, January 20, 2012 ª2012 Elseviercells through the basement membrane
into the surrounding stroma, followed by
extravasation into the circulatory systems
(blood, lymph), and finally by the re-
establishment of colonies of neoplastic
cells at distant sites. This process is
not thought to be operant in preneo-
plasms—the common putative precursor
lesions that share many histological and
molecular features with advanced carci-
nomas excepting breach of the basement
membrane. Indeed, preneoplasms are
oftentimes termed preinvasive neoplasms
for this reason, with pancreatic intraepi-
thelial neoplasms (PanINs) denoting the
most common premalignant precursors
for PDAC. Contrary to this prevailing
dogma, Rhim et al. report here that
even low-grade PanINs that harbor only
oncogenic Krasmutations show evidence
of cells that have ‘‘delaminated’’ and
migrated away from the glandular preneo-
plasm into the surrounding tissue and
circulatory system. The authors used
clever gene reporter approaches in
several genetically engineered mouse
models of PanIN to determine that the
‘‘preneoplastic’’ cells that had migrated
into the stroma had the appearance of
mesenchymal cells as opposed to the
PanIN cells that exhibited an epithelial
morphology. As such, they may represent
an in vivo example of the long-sought
‘‘epithelial-to-mesenchymal transition’’
(EMT) cells that have been contentiouslyInc.debated in the biomedical community.
These mesenchymal PanIN cells coex-
pressed proteins characteristically asso-
ciated with EMT, including Zeb1, slug,
and snail. Importantly, they could be
independently identified in both murine
and some human PanIN specimens
by utilizing the transcription factor Pdx1
as a pancreatic epithelial lineage marker.
The circulating PanIN cells also ex-
pressed the ‘‘cancer-initiating cell’’ sur-
face proteins CD24 and CD44 (Li et al.,
2007), reminiscent of the association
between EMT and cellular plasticity
proposed by Robert Weinberg and
colleagues (Mani et al., 2008). Rhim et al.
found that inflammation with the secreta-
gogue cerulean or following pancreatic
duct ligation increases the number of
circulating pancreatic preneoplastic cells,
reinforcing the link between inflammation
and PDAC as previously demonstrated
in familial chronic pancreatitis patients
and mouse models (reviewed in Mazur
and Siveke, 2011). Furthermore, treat-
ment with anti-inflammatory agents de-
creases the number of circulating PanIN
cells and decreases the abundance of
PanINs in tissue. Interestingly, the circu-
lating PanIN cells isolated from Kras
mutant mice are not competent to form
colonies in culture and thus are likely
unable to establish proliferating metas-
tases prior to acquiring mutations in addi-
tional genes such as Trp53 or p16Ink4a/Arf.
As Kras mutant PanIN cells in circula-
tion may be incapable of distant site colo-
nization, the critical issue becomes the
timing of clinically relevant metastasis.
Using a mathematical modeling approach
with radiological and pathological data
on pancreatic cancer patients who under-
went autopsy, Haeno et al. propose that
PDAC grows at an exponential rate, and
that cells with high metastatic compe-
tency were generated during tumor
expansion (on the order of 1 in a million
PDAC cells). They then predict that even
very small primary tumors have frequently
undergone microscopic metastasis prior
to surgical removal and propose that
upfront systemic chemotherapy may
provide an improved outcome for patients
who present with such ‘‘early stage’’
disease. The autopsy series also revealed
that a tiny subset of patients (14/101) died
with only locally advanced disease, sug-
gesting that there may be some patients
who lack factors to promote metastases,
carry traits that suppress metastases, or
have exaggerated responses to systemic
therapies.
Both of these studies transform the
way that we consider pancreatic cancer
evolution and provide the opportunity to
refocus and prioritize our efforts toward
improving the outcomes of our patients
(Figure 1). Indeed, investigational clinical
trials that compare neoadjuvant cytotoxic
and antimetastatic therapies to upfront
surgery should be considered immedi-
ately for all patients. Also, patients at risk
for developing pancreatic cancer could
be considered for enrolment in studies
that evaluate anti-inflammatory and anti-
metastatic strategies, as the bartering
process between seed and soil begins
during the PanIN stage. Furthermore, in
addition to comparing the molecular
details between primary tumors and
pairedmetastases, we nowhave a greater
impetus to understand the genetic, epige-
netic, and nongenetic factors that may
explain our long-term survivors and those
who never developmetastases. However,
these studies are a stark reminder thatour current methods for initially detecting
pancreatic cancer are insufficient and
must change. Mouse pancreatic cancer
models have served as a fruitful com-
panion system for pancreatic cancer
research, and they should continue to
be exploited to accomplish these goals.
Of course, the findings heremaybegener-
ally applicable to other carcinomas, and
lineage markers that attempt to distin-
guish epithelial cells from stromal fibro-
blasts could be useful to search for ‘‘EMT
cells’’ in this regard. Finally, although
these new findings in pancreatic cancer
may evoke dismay, they actually offer
a different perspective that we may wield
against this silent killer, to its undoing.REFERENCES
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